(Q37156975)

18 August 2017

1 reference

title

Safety of MF59 adjuvant (English)

1 reference

18 August 2017

Andreas Wack

3

0 references

author name string

Viola Schultze

1

1 reference

18 August 2017

Vicente D'Agosto

2

1 reference

18 August 2017

Deborah Novicki

4

1 reference

18 August 2017

Juergen Zorn

5

1 reference

18 August 2017

Renald Hennig

6

1 reference

18 August 2017

language of work or name

English

0 references

publication date

21 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

26

1 reference

18 August 2017

issue

26

1 reference

18 August 2017

page(s)

3209-3222

1 reference

Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Induction and detection of antibodies to squalene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Some Observations on the Use of Alum Precipitated Diphtheria Toxoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

The perfect mix: recent progress in adjuvant research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Association between immunogenicity and adsorption of a recombinant Streptococcus pneumoniae vaccine antigen by an aluminum adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Dendritic cells internalize vaccine adjuvant after intramuscular injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

A universal vaccine for serogroup B meningococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Cationic microparticles are a potent delivery system for a HCV DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Immunization of woodchucks with adjuvanted sHDAg (p24): immune response and outcome following challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Antibodies to squalene in Gulf War syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Adjuvants designed for veterinary and human vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Development of an Adjuvant to Enhance the Immune Response to Influenza Vaccine in the Elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Adjuvant effects of IL-1beta, IL-2, IL-8, IL-15, IFN-alpha, IFN-gamma TGF-beta4 and lymphotactin on DNA vaccination against Eimeria acervulina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Acute disseminated encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

7 January 2021

Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Vaccination of patients with encephalomyelitis disseminata

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Guillain-Barré syndrome following influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Parsonage-Turner syndrome: MR imaging findings and clinical information of 27 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

A possible association between influenza vaccination and small-vessel vasculitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Reactivation of vasculitis after influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.093

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2008.03.093

1 reference

18 August 2017

1 reference